If a company is offering a test for viral resistance to particular drugs, wouldn they be able to provide adequate guidance on how to interpret the results?
Merigan: They try to, but our understanding can change. In drug development, you have to look at the pharmacology, as well as resistance patterns from genotypic or phenotypic tests. And sometimes companies do not do all of the necessary pharmacology, especially during the first few years in the drug’s development. In AIDS we are pushing the envelope in developing these drugs. And sometimes we would need data that has not yet been obtained, to come to firm conclusions. ATN: How much of a problem do doctors have at this time in deciding which genotypic or phenotypic lab to use? Merigan: The only phenotypic group now doing work on patient-submitted specimens is VIRCO in Belgium; they are working through LabCorp in the U.S. But there are many laboratories doing genotypic testing. Because there have never been head-to-head trials of the two assays, comparing genotypic and phenotypic testing directly against each other, we do no know which niche applications might be better for one test or t
Related Questions
- If a company is offering a test for viral resistance to particular drugs, wouldn they be able to provide adequate guidance on how to interpret the results?
- If there is a definite "testing window", will a company that misses that window still be able to send test data after the system goes live?
- If there is a definite "testing window", will a company that misses that window still be able to send test data after the system goes live?
- Our company is thinking of testing for alcohol along with drugs. Can we have the laboratory test urine for both drugs and alcohol?
- If the union does not allow pre-employment screening, is a company still able to put applicants through the strength test?
- If the union does not allow pre-employment screening, is a company still able to put applicants through the strength test?
